全文获取类型
收费全文 | 63849篇 |
免费 | 4730篇 |
国内免费 | 1750篇 |
专业分类
耳鼻咽喉 | 838篇 |
儿科学 | 1187篇 |
妇产科学 | 2214篇 |
基础医学 | 8045篇 |
口腔科学 | 1160篇 |
临床医学 | 6831篇 |
内科学 | 11941篇 |
皮肤病学 | 1190篇 |
神经病学 | 3957篇 |
特种医学 | 2613篇 |
外国民族医学 | 6篇 |
外科学 | 8525篇 |
综合类 | 4196篇 |
现状与发展 | 7篇 |
一般理论 | 11篇 |
预防医学 | 3501篇 |
眼科学 | 1400篇 |
药学 | 5330篇 |
20篇 | |
中国医学 | 1678篇 |
肿瘤学 | 5679篇 |
出版年
2023年 | 522篇 |
2022年 | 1320篇 |
2021年 | 2147篇 |
2020年 | 1308篇 |
2019年 | 1620篇 |
2018年 | 2000篇 |
2017年 | 1517篇 |
2016年 | 1567篇 |
2015年 | 2330篇 |
2014年 | 2915篇 |
2013年 | 3392篇 |
2012年 | 4815篇 |
2011年 | 4689篇 |
2010年 | 2986篇 |
2009年 | 2613篇 |
2008年 | 3538篇 |
2007年 | 3537篇 |
2006年 | 3382篇 |
2005年 | 3124篇 |
2004年 | 2823篇 |
2003年 | 2705篇 |
2002年 | 2349篇 |
2001年 | 1843篇 |
2000年 | 1609篇 |
1999年 | 1336篇 |
1998年 | 553篇 |
1997年 | 457篇 |
1996年 | 416篇 |
1995年 | 377篇 |
1994年 | 348篇 |
1993年 | 242篇 |
1992年 | 711篇 |
1991年 | 582篇 |
1990年 | 531篇 |
1989年 | 484篇 |
1988年 | 421篇 |
1987年 | 424篇 |
1986年 | 355篇 |
1985年 | 295篇 |
1984年 | 229篇 |
1983年 | 191篇 |
1982年 | 114篇 |
1981年 | 122篇 |
1980年 | 99篇 |
1979年 | 205篇 |
1978年 | 161篇 |
1977年 | 103篇 |
1976年 | 110篇 |
1975年 | 102篇 |
1974年 | 99篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
目的 运用标准化患者法评估四川农村地区基层医生不稳定型心绞痛和2型糖尿病两种慢性病诊断准确性现状,探讨基层医生两种慢性病诊断准确性的主要影响因素,为提升基层医生两种慢性病诊断准确性提供科学依据。方法 采用多阶段随机整群抽样方法,抽取四川省自贡市5个区/县50个乡镇100个村为研究现场,以调查当日在岗的全科及内科医生作为研究对象。共进行两轮数据采集,第1轮采集样本乡镇卫生院和村卫生室医生的基本信息;第1轮调查完成1个月后,运用标准化患者法开展第2轮调查,收集农村基层医生对不稳定型心绞痛和2型糖尿病诊断结果信息。运用Logistic回归分析农村基层医生不稳定型心绞痛和2型糖尿病诊断准确性的影响因素。结果 共纳入172名农村基层医生,完成186次标准化患者访问,正确诊断率为48.39%。其中不稳定型心绞痛的正确诊断率为18.68%(17/91),2型糖尿病的正确诊断率为76.84%(73/95)。Logistic回归分析显示,具有执业医师资质的农村基层医生更有可能做出正确诊断(OR=4.857,95%CI=1.076~21.933,P=0.040)。农村基层医生在诊断过程中涉及的必要问诊和检查条目越多,做出正确诊断的概率越高(OR=1.627,95%CI=1.065~2.485,P=0.024)。与不稳定型心绞痛相比,农村基层医生对2型糖尿病做出正确诊断的可能性更高(OR=6.306,95%CI=3.611~11.013,P<0.001)。结论 四川农村基层医生不稳定型心绞痛和2型糖尿病诊断准确性整体较差,建议以基层医生慢性病诊断过程质量改善为突破口,提升基层医生执业水平,进而提高慢性病诊断准确性。 相似文献
3.
Kuo-yi Jade Chang MHealthEc MHM BSc Lisa Lorraine Dillon MSpecEd BPsych Lil Deverell COMS PhD MEd GradDipO&M BEd Mei Ying Boon PhD BOptom FAAO Lisa Keay PhD MPH BOptom 《Clinical & experimental optometry》2020,103(4):434-448
Despite orientation and mobility (O&M) being a significant factor determining quality of life of people with low vision or blindness, there are no gold standard measures or agreement on how to measure O&M performance. In the first part of this systematic review, an inventory of O&M outcome measures used by recent studies to assess the performance of orientation and/or mobility of adults with vision impairment (low vision and blindness) is presented. A wide variety of O&M outcome measures have been implemented in different fields of study, such as epidemiologic research and interventional studies evaluating training, assistive technology, vision rehabilitation and vision restoration. The most frequent aspect of outcome measures is efficiency such as time, distance, speed and percentage of preferred walking speed, followed by obstacle contacts and avoidance, and dis/orientation and veering. Other less commonly used aspects are target identification, safety and social interaction and self-reported outcome measures. Some studies employ sophisticated equipment to capture and analyse O&M performance in a laboratory setting, while others carry out their assessment in real-world indoor or outdoor environments. In the second part of this review, the appropriateness of implementing the identified outcome measures to assess O&M performance in clinical and functional O&M practice is evaluated. Nearly a half of these outcome measures meet all four criteria of face validity (either clinical or functional), responsiveness, reliability and feasibility and have the potential to be implemented in clinical or functional O&M practice. The findings of this review confirm the complicated and dynamic nature of O&M. Multiple measures are required in any evaluation of O&M performance to facilitate holistic assessment of O&M abilities and limitations of each individual. 相似文献
4.
5.
6.
7.
8.
9.
10.
Xue Yao Yan Zhang Jian Hao Hui-Quan Duan Chen-Xi Zhao Chao Sun Bo Li Bao-You Fan Xu Wang Wen-Xiang Li Xuan-Hao Fu Yong Hu Chang Liu Xiao-Hong Kong Shi-Qing Feng 《中国神经再生研究》2019,(3)
Ferroptosis is an iron-dependent novel cell death pathway. Deferoxamine, a ferroptosis inhibitor, has been reported to promote spinal cord injury repair. It has yet to be clarified whether ferroptosis inhibition represents the mechanism of action of Deferoxamine on spinal cord injury recovery. A rat model of Deferoxamine at thoracic 10 segment was established using a modified Allen's method. Ninety 8-week-old female Wistar rats were used. Rats in the Deferoxamine group were intraperitoneally injected with 100 mg/kg Deferoxamine 30 minutes before injury. Simultaneously, the Sham and Deferoxamine groups served as controls. Drug administration was conducted for 7 consecutive days. The results were as follows:(1) Electron microscopy revealed shrunken mitochondria in the spinal cord injury group.(2) The Basso, Beattie and Bresnahan locomotor rating score showed that recovery of the hindlimb was remarkably better in the Deferoxamine group than in the spinal cord injury group.(3) The iron concentration was lower in the Deferoxamine group than in the spinal cord injury group after injury.(4) Western blot assay revealed that, compared with the spinal cord injury group, GPX4, xCT, and glutathione expression was markedly increased in the Deferoxamine group.(5) Real-time polymerase chain reaction revealed that, compared with the Deferoxamine group, mRNA levels of ferroptosis-related genes Acyl-CoA synthetase family member 2(ACSF2) and iron-responsive element-binding protein 2(IREB2) were up-regulated in the Deferoxamine group.(6) Deferoxamine increased survival of neurons and inhibited gliosis. These findings confirm that Deferoxamine can repair spinal cord injury by inhibiting ferroptosis. Targeting ferroptosis is therefore a promising therapeutic approach for spinal cord injury. 相似文献